Cambridge, UK-based Crescendo Biologics will expand its discovery and development collaboration with Japanese pharma company Takeda, which is focused on building Humabody-based therapeutics against undisclosed targets.
Welcome to the latest edition of our weekly EuroBiotech Report. We start this week with Crescendo Biologics, which raised $70 million (€57 million) to progress an anti-cancer ...